Gracell Biotechnologies Inc expected to post a loss of 7  cents a share - Earnings Preview

Gracell Biotechnologies

12/08/2022 14:05

* Gracell Biotechnologies Inc  GRCL.OQ   GRCL.O  is expected
to show no change in quarterly revenue when it reports 
results on August 15. 
    * ​Refinitiv's mean analyst estimate for Gracell
Biotechnologies
Inc is for a loss of 7 cents per share. For the same quarter
last year, the company reported a loss of 20 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Gracell
Biotechnologies Inc is $20​, above​ its last closing price
of $3.40. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2022  -0.23       -0.21      -0.35     Missed  -66.7
 Dec. 31 2022  -0.33       -0.33      -0.30     Beat    9.1
 Sep. 30 2021  -0.15       -0.12      -0.30     Missed  -150​
 Jun. 30 2021  -0.12       -0.12      -0.20     Missed  -71.4
 ​​Mar.        -0.21       -0.21      -0.25     Missed  -17.2
 31 2021                                                
 Dec. 31 2020  -0.26       -0.26      -0.16     Beat    37.5​
 This summary was machine generated August 12 at 13:05 GMT.  All
figures in US dollars  unless otherwise stated